Aldevron, the leading plasmid DNA, proteins and mRNA manufacturing company, is pleased to announce the hiring of Kenneth (Ken) Bonnell as Vice President of Quality and Regulatory Affairs.
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Cynthia Biffert as Vice President of its GMP Nucleic Acids Business Unit (NABU).
Partnership with Harvard scientists at Mass. Eye and Ear and Mass General supports AAV based gene therapies to produce SARS-CoV-2 vaccine
Aldevron is excited to announce our partnership with MEEI to support its manufacturing of an experimental vaccine for clinical studies for its AAVCOVID vaccine program.
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President of its Research Grade nucleic acids business unit.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations. This is a new position and is a part of the senior management team.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, protein, mRNA and antibodies for the biotech industry, is hosting its second Breakthrough Symposium with the theme “Pioneering Biotech,” September 28-30, 2020, in Fargo, N.D., home to Aldevron’s headquarters and main campus.
FARGO, N.D. (February 12, 2019)—Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies to the biotech industry, announced today the addition of DasherGFP® (green fluorescent protein) mRNA to its off-the-shelf, product portfolio.
In June of 2019, Aldevron announced its massive 14-acre campus expansion. The construction began with a groundbreaking ceremony in August of 2019, launching the buildout of the campus’ second GMP manufacturing facility. This 189,000 square-foot, two-story building is slated to increase Aldevron’s GMP and GMP-Source production capacity up to 10 times its current output. In December of 2019, a major milestone was reached when structural steel beams were installed (pictured).
Fargo, N.D., based company increasing capacity to better serve
rapidly growing biotech industry
Aldevron officially broke ground on its 14-acre campus expansion at its global headquarters in Fargo, North Dakota, August 19. Three buildings are planned, with construction of its next GMP manufacturing facility starting first.
Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic platform (Beacon) to support rapid execution of species agnostic single B-cell antibody discovery to complement its industry-leading genetic immunization and hybridoma capabilities.
The Beacon platform will be located in the recently announced expansion lab space in Aldevron’s Freiburg, Germany, facility and will be coming on-line in June 2019. Aldevron is the first CRO in Germany to adapt this new technology for antibody discovery.